Our therapeutic goals for the treatment of ulcerative colitis and Crohn’s disease are evolving. Until the last decade the goals were primarily the treatment of symptoms. Regulatory approval for ulcerative colitis therapies have been based on short-term improvements in clinical indices and, most recently, the ability to heal the colonic mucosa, whereas approval for Crohn’s disease therapies have been based on reductions in the CDAI (Crohn’s Disease Activity Index). Over the past decade there has been increasing evidence in favor of more ‘objective’ measures of biologic disease activity including biomarkers such as C-reactive protein and mucosal healing in Crohn’s disease and the histologic resolution of active inflammation in ulcerative colitis. The objective changes have provided expanded therapeutic goals based on longer-term maintenance therapies with the potential to modify the chronic disease behavior and to reduce pharmacoeconomic costs (reductions in hospitalizations, surgeries and neoplasia).

D’Haens G, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763–786.
Higgins PD, et al: Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005;100:355–361.
Sandborn WJ, et al: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002;122:512–530.
Modigliani R, et al: Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etudes Thrapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811–818.
Landi B, et al: Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647–1653.
Summers RW, et al: National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Pt 2):847–869.
Malchow H, et al: European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249–266.
Cosnes J, et al: Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005;54:237–241.
Munkholm P, et al: Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35:360–362.
Faubion WA Jr, et al: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255–260.
Froslie KF, et al: Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–422.
Colombel JF, et al: Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194–1201.
Meucci G, et al: Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2011, E-pub ahead of print.
Rutter M, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451–459.
Candy S, et al: A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–678.
Feagan BG, et al: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000;342:1627–1632.
Markowitz J, et al: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895–902.
D’Haens G, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–667.
Rutgeerts P, et al: Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006;63:433–442;quiz 464.
Baert F, et al: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–468;quiz e10–11.
Peyrin-Biroulet L, et al: The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 2010;105:289–297.
Vermeire S, van Assche G, Rutgeerts P: Review article: altering the natural history of Crohn’s disease – evidence for and against current therapies. Aliment Pharmacol Ther 2007;25:3–12.
Colombel JF, et al: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362:1383–1395.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.